Form 4: Tenaya Therapeutics CEO Sells Shares for Tax Obligations

Tenaya Therapeutics CEO Faraz Ali sold 3,126 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Faraz Ali, Chief Executive Officer and Director of Tenaya Therapeutics, Inc. (TNYA), reported a transaction on November 17, 2025.
• Ali sold 3,126 shares of Tenaya Therapeutics common stock at a price of $1.33 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) that were awarded on February 6, 2025.
• Following this transaction, Ali beneficially owns 299,666 shares of common stock, which includes 211,275 shares from unvested restricted stock units.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an insider to cover tax obligations related to vested equity awards, which is a common occurrence and does not typically indicate a change in company fundamentals or insider sentiment.

Positives

• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged sale not based on new insider information.
• The sale was explicitly for tax withholding obligations, which is a common and routine event for executives receiving equity compensation.

Negatives

• No direct negatives for the company's operational performance are indicated; the sale is a routine event for tax purposes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report (Form 4) is a routine disclosure required by the SEC for executives and directors. It does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale, not a discretionary sale indicating a change in confidence in the company's prospects.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Faraz Ali, Form 4, Insider Transaction, Stock Sale, CEO, Restricted Stock Units, RSU, Tax Withholding, Rule 10b5-1